A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Outcomes?

ClinicalTrials.gov ID: NCT02287025

Public ClinicalTrials.gov record NCT02287025. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Does Physician Education Influence Side Effect Management and Does it Increase Time on Treatment in the Absence of Progression ? A Phase 4 Open-label Trial With Regorafenib in Metastatic Colorectal Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Randomized trial to evaluate impact of healthcare provider( clinician and nursing staff) support and education on treatment discontinuation rates in the absence of progression in patients with metastatic colorectal cancer treated with regorafenib. Intensified education and support will be provided through an application for iPad which has automatic links to grading, dose reduction and side effect management ,as well as, references for additional articles.

Study identification

NCT ID: NCT02287025
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 4
Lead sponsor: Bayer; Industry
Enrollment: 23 participants

Conditions and interventions

Conditions

Physician Education

Interventions

Drug · Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 11, 2014 (Actual)
Primary completion: Feb 26, 2016 (Actual)
Completion: Apr 8, 2016 (Actual)
Last update posted: Oct 19, 2017

2014 – 2016

United States locations

U.S. sites: 17
U.S. states: 13
U.S. cities: 16

Facility	City	State	ZIP	Site status
Not listed	Anniston	Alabama	36207	—
Not listed	Anaheim	California	92801	—
Not listed	Orange	California	92668	—
Not listed	Lake City	Florida	32024	—
Not listed	Skokie	Illinois	60076	—
Not listed	Skokie	Illinois	60077	—
Not listed	Lafayette	Indiana	47905	—
Not listed	Columbia	Maryland	21044	—
Not listed	Fayetteville	North Carolina	28304	—
Not listed	Canton	Ohio	44718	—
Not listed	Tulsa	Oklahoma	74146	—
Not listed	Gettysburg	Pennsylvania	17325	—
Not listed	Kingsport	Tennessee	37660	—
Not listed	Houston	Texas	77024	—
Not listed	Tyler	Texas	75701	—
Not listed	Bristol	Virginia	24201	—
Not listed	Portsmouth	Virginia	23704	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02287025, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 19, 2017 · Synced Oct 17, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02287025 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →